Tadeusz Robak

37.1k total citations · 10 hit papers
712 papers, 19.3k citations indexed

About

Tadeusz Robak is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Tadeusz Robak has authored 712 papers receiving a total of 19.3k indexed citations (citations by other indexed papers that have themselves been cited), including 432 papers in Genetics, 275 papers in Pathology and Forensic Medicine and 214 papers in Hematology. Recurrent topics in Tadeusz Robak's work include Chronic Lymphocytic Leukemia Research (413 papers), Lymphoma Diagnosis and Treatment (261 papers) and Immunodeficiency and Autoimmune Disorders (110 papers). Tadeusz Robak is often cited by papers focused on Chronic Lymphocytic Leukemia Research (413 papers), Lymphoma Diagnosis and Treatment (261 papers) and Immunodeficiency and Autoimmune Disorders (110 papers). Tadeusz Robak collaborates with scholars based in Poland, United States and United Kingdom. Tadeusz Robak's co-authors include Ewa Robak, Piotr Smolewski, Paweł Robak, Peter Hillmen, Barbara Eichhorst, Michael Hallek, Emili Montserrat, Ewa Lech‐Marańda, Agnieszka Wierzbowska and Anna Korycka and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Tadeusz Robak

674 papers receiving 18.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

2018 971 citations Michael Hallek, Peter Hillmen et al. Blood profile →
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

2011 661 citations Sebastian Grosicki, Tadeusz Robak et al. profile →
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

2018 595 citations John F. Seymour, Thomas J. Kipps et al. profile →
Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

2007 505 citations Tadeusz Robak, Anna Dmoszyńska et al. Journal of Clinical Oncology profile →
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

2011 441 citations Tadeusz Robak et al. Blood profile →
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2015 420 citations Barbara Eichhorst, Tadeusz Robak et al. profile →
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

2018 354 citations Andrzej Hellmann, Tadeusz Robak et al. profile →
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2020 339 citations Barbara Eichhorst, Tadeusz Robak et al. profile →
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

2019 312 citations Jan A. Burger, Paul M. Barr et al. profile →
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

2022 146 citations Paul M. Barr, Carolyn Owen et al. profile →

Peers

Countries citing papers authored by Tadeusz Robak

Since Specialization

Citations

This map shows the geographic impact of Tadeusz Robak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tadeusz Robak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tadeusz Robak more than expected).

Fields of papers citing papers by Tadeusz Robak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tadeusz Robak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tadeusz Robak. The network helps show where Tadeusz Robak may publish in the future.

Co-authorship network of co-authors of Tadeusz Robak

This figure shows the co-authorship network connecting the top 25 collaborators of Tadeusz Robak. A scholar is included among the top collaborators of Tadeusz Robak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tadeusz Robak. Tadeusz Robak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Zapobieganie i leczenie działań niepożądanych związanych z terapią skojarzoną ibrutynibem i wenetoklaksem w przewlekłej białaczce limfocytowej 2025 ·SHILAP Revista de lepidopterología ·Elżbieta Iskierka‐Jazdzewska, Krzysztof Jamroziak, Tadeusz Robak, Bartosz Puła	0
2	Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2025 roku — Raport Grupy Roboczej PTHiT i PALG-CLL 2025 ·SHILAP Revista de lepidopterología ·Iwona Hus, Krzysztof Giannopoulos, Krzysztof Jamroziak, Dariusz Wołowiec, Jacek Roliński, Tadeusz Robak	1
3	Atypical Hairy Cell Leukemia—The Current Status and Future Directions 2025 ·European Journal Of Haematology ·Tadeusz Robak, (unknown), Agata Majchrzak, (unknown), Marcin Braun	0
4	Venetoclax used alone, or in combination with cladribine, changes the expression of apoptosis-regulating genes in chronic lymphocytic leukemia cells in vitro 2025 ·Advances in Clinical and Experimental Medicine ·(unknown), (unknown), Dariusz Wołowiec, Izabela Zawlik, (unknown), (unknown), Tadeusz Robak, Anna Korycka	0
5	Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL 2025 ·Blood ·Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Anita Sarma, Piers Patten, Sebastian Grosicki, Helen O. McCarthy, Fritz Offner, (unknown), Cathy Zhou, (unknown), Lynne Neumayr, James P. Dean, Paolo Ghia, Thomas J. Kipps	5
6	Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin 2024 ·Journal of Clinical Medicine ·(unknown), Tadeusz Robak, Wojciech Biernat, Ewa Robak	4
7	Increased abundance of Firmicutes and depletion of Bacteroidota predicts poor outcome in chronic lymphocytic leukemia 2024 ·Oncology Letters ·(unknown), (unknown), Michał Kiełbus, (unknown), Joanna Zaleska, Ewa Wawrzyniak, (unknown), (unknown), Marta Morawska, Elżbieta Kalicińska, (unknown), Tomasz Wróbel, Anna Wolska, Jerzy Z. Błoński, Tadeusz Robak, Lars Bullinger, Krzysztof Giannopoulos	4
8	Expert opinion on use of acalabrutinib for chronic lymphocytic leukemia treatment 2024 ·Acta Haematologica Polonica ·Bartosz Puła, Elżbieta Iskierka‐Jazdzewska, Krzysztof Jamroziak, Krzysztof Giannopoulos, Tomasz Wróbel, Tadeusz Robak, Iwona Hus	2
9	CLL-076 Final Analysis of the RESONATE-2 Study: up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Anita Sarma, Piers Patten, Sebastian Grosicki, Helen O. McCarthy, Fritz Offner, Edith Szafer‐Glusman, Cathy Zhou, Anita Szőke, Lynne Neumayr, James P. Dean, Paolo Ghia, Thomas J. Kipps	4
10	An elevated systemic inflammation index is related to an inferior response to pomalidomide and dexamethasone treatment in patients with relapsed and refractory multiple myeloma 2023 ·Współczesna Onkologia ·Damian Mikulski, Paweł Robak, (unknown), (unknown), (unknown), (unknown), (unknown), Tadeusz Robak	0
11	MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) 2023 ·Hematological Oncology ·Arnon P. Kater, Rosemary Harrup, Thomas J. Kipps, Barbara Eichhorst, Carolyn Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Maria Thadani‐Mulero, Marcus Lefebure, Yanwen Jiang, Rosemary Millen, Michelle Boyer, John F. Seymour	8
12	Safety of the Anti-CD19 antibody Tafasitamab in Long Term Responders from A Phase II Trial for Relapsed Lymphoma 2021 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Tadeusz Robak, Chiara Ghiggi, (unknown), (unknown), Matthias Theobald, Georg Heß	3
13	Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia 2016 ·British Journal of Haematology ·Tadeusz Robak, Andrzej Hellmann, Janusz Kłoczko, Javier Loscertales, Ewa Lech‐Marańda, John M. Pagel, Anthony R. Mato, John C. Byrd, Farrukh T. Awan, Holger Hebart, (unknown), Brian T. Hill, Michael Hallek, Amy J. Eisenfeld, Scott Stromatt, Ulrich Jaeger	30
14	The preclinical discovery of rituximab for the treatment of non-Hodgkin’s lymphoma 2015 ·Expert Opinion on Drug Discovery ·Piotr Smolewski, Tadeusz Robak	8
15	Emerging immunological drugs for chronic lymphocytic leukemia 2015 ·Expert Opinion on Emerging Drugs ·Paweł Robak, Piotr Smolewski, Tadeusz Robak	2
16	Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911) 2013 ·Blood ·Peter Hillmen, Tadeusz Robak, Ann Janssens, (unknown), Sebastian Grosicki, Jiřı́ Mayer, Panagiotis Panagiotidis, Eva Kimby, Anna Schuh, Thomas E. Boyd, Marco Montillo, Astrid McKeown, Jodi Carey, Ira Gupta, Chai‐Ni Chang, Steen Lisby, Fritz Offner	58
17	Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma 2010 ·Journal of Clinical Oncology ·Sean Whittaker, Marie‐France Demierre, Ellen J. Kim, Alain H. Rook, Adam Lerner, Madeleine Duvic, Julia Scarisbrick, Sunil Reddy, Tadeusz Robak, Jürgen C. Becker, А. В. Самцов, William McCulloch, Youn H. Kim	480
18	Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia 2007 ·Journal of Clinical Oncology ·Peter Hillmen, Aleksander B. Skotnicki, Tadeusz Robak, Branimir Jakšić, Anna Dmoszyńska, Jingyang Wu, Cynthia A. Sirard, Jiřı́ Mayer	408
19	Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study 2007 ·Blood ·Bertrand Coiffier, Stéphane Leprêtre, Lars Møller Pedersen, Ole Gadeberg, (unknown), Marinus H. J. van Oers, James E. Wooldridge, Janusz Kłoczko, Jerzy Hołowiecki, Andrzej Hellmann, Jan Walewski, Mimi Folden Flensburg, Jørgen Holm Petersen, Tadeusz Robak	287
20	The distribution of peripheral blood dendritic cells assayed by a new panel of anti-BDCA monoclonal antibodies in healthy representatives of the polish population. 2004 ·PubMed ·Joanna Narbutt, Aleksandra Lesiak, Małgorzata Żak-Prelich, Anna Woźniacka, Anna Sysa‐Jędrzejowska, (unknown), Tadeusz Robak, Piotr Smolewski	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact